Skeletal muscle-targeted peptide MSP

  • Description

  • Application Data

Description

A heptapeptide sequence shown to have a high affinity for skeletal muscle cells.

See full description

Application Data

Catalogue number crb1001632
Molecular Weight 674.4
Disease Area Muscle disorder
Sequence (three letter code)

H-Ala-Ser-Ser-Leu-Asn-Ile-Ala-OH

Storage -20°C
Citations

Samoylova et al., (1999). Elucidation of muscle‐binding peptides by phage display screening. Muscle Nerve. 22(4): 460. https://doi.org/10.1002/(SICI)1097-4598(199904)22:4<460::AID-MUS6>3.0.CO;2-L.

 

Jativa et al., (2019). Enhanced Delivery of Plasmid DNA to Skeletal Muscle Cells using a DLC8-Binding Peptide and ASSLNIA-Modified PAMAM Dendrimer. Mol. pharm16(6): 2376. https://doi.org/10.1021/acs.molpharmaceut.8b01313.

 

Yin et al., (2008) Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice. Mol. Ther. 16(1): 38. PMID: 17968354.

References

Samoylova et al., (1999). Elucidation of muscle‐binding peptides by phage display screening. Muscle Nerve. 22(4): 460. https://doi.org/10.1002/(SICI)1097-4598(199904)22:4<460::AID-MUS6>3.0.CO;2-L.

 

Jativa et al., (2019). Enhanced Delivery of Plasmid DNA to Skeletal Muscle Cells using a DLC8-Binding Peptide and ASSLNIA-Modified PAMAM Dendrimer. Mol. pharm16(6): 2376. https://doi.org/10.1021/acs.molpharmaceut.8b01313.

 

Yin et al., (2008) Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice. Mol. Ther. 16(1): 38. PMID: 17968354.

Material Safety Data Sheet (MSDS)

Gene therapy is potentially an ideal treatment for muscle tissue myopathies but targeting remains an issue. The large volume of muscle in the body versus the requirement for tissue-specificity is of particular concern. This heptapeptide has been shown to preferentially bind skeletal myofibers and thus can be used to study targeting of peptide/gene-delivery to muscle tissue. Research into gene therapy of Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA) has been of particular interest with muscle targeting peptides. This product already shows ideal placement to continue that research to overcome some of these issues.

Skeletal muscle-targeted peptide MSP

Cat No.Pack SizePriceQty.
£110.00
£85.00
Bulk Quote